Getting a Second Opinion on a Melanoma Diagnosis: Pathology Review and Plan Questions

The report arrives in the patient portal at 9:40 on a Tuesday, and the word sits there in a sentence that also mentions millimeters and margins. Melanoma. Most people read it three times, then search their phone for what a melanoma second opinion involves and whether asking for one will slow everything down or annoy the dermatologist who found the spot in the first place.

Here is the part that rarely makes it into the first conversation: a melanoma diagnosis is not a single fact. It is an interpretation of cells on a glass slide, followed by a plan built on that interpretation. Both layers can be checked. Neither check requires you to fire anyone.

This explainer walks through what a pathology review actually is, why skilled pathologists sometimes disagree, who tends to gain the most from a second read, how to request it without losing time, and which questions to bring to the team that will ultimately treat you.

What does a melanoma second opinion actually cover?

People often picture a second opinion as a second surgeon nodding or shaking their head at a plan. In melanoma, the more consequential review happens earlier and quieter, at a microscope. A pathologist is the physician who examines tissue under magnification and decides what it is. Everything downstream, from how wide the surgeon cuts to whether anyone mentions lymph nodes or drug therapy, rests on that reading.

So a thorough melanoma second opinion has two layers. The first is a pathology review: another pathologist, ideally a dermatopathologist (a pathologist with additional training in skin disease), looks at the same slides and writes an independent report. The second is a plan review: a melanoma-focused dermatologist, surgical oncologist or medical oncologist looks at the confirmed diagnosis, the stage and your health history, then says whether the proposed steps match current guidelines. Many centers do this through a tumor board, a scheduled meeting where several specialties discuss one patient’s case together.

Both layers matter, but they answer different questions. The slide review asks, is this melanoma, and if so how thick and how aggressive does it look? The plan review asks, given that answer, is the proposed surgery, staging and follow-up appropriate? A second opinion can agree completely, adjust a measurement by a fraction of a millimeter that changes the surgical plan, or occasionally reclassify the lesion altogether.

What a second opinion is not: a verdict that overrides your original doctor, or a reason to pause care without telling anyone. It is additional evidence handed back to the team responsible for you. The Mayo Clinic and the National Cancer Institute both describe biopsy and pathology as the basis of every melanoma diagnosis, which is exactly why that basis deserves a careful look before the plan hardens.

How does a pathology review actually happen?

After a biopsy, the removed tissue is preserved, embedded in a small block of paraffin wax, sliced thinner than a sheet of paper, mounted on glass slides and stained so the cells show color under a microscope. The most common stain, hematoxylin and eosin, turns nuclei purple and the surrounding tissue pink. The block and the slides become part of your medical record, stored at the laboratory that made them.

A pathology review begins when those slides, or high-resolution digital scans of them, are sent to a second pathologist. Digital pathology, where a whole slide is scanned into an image a specialist can zoom through on a screen, has made this transfer faster in many places, though physical slides are still shipped routinely. No new biopsy is usually needed; the tissue already exists.

The reviewing pathologist starts with the same questions the first one faced. Are these melanocytes, the pigment-producing cells that melanoma arises from? Are they confined to the top layer of skin (melanoma in situ) or have they pushed into the dermis beneath (invasive melanoma)? How deep is the deepest cell? Are cells dividing rapidly? Is the surface broken?

When the picture is ambiguous, the reviewer can ask the original lab to cut deeper sections from the wax block, revealing tissue the first slides did not capture. They may order immunohistochemistry, special stains that tag specific proteins and help distinguish melanoma cells from the cells of an ordinary mole. In select borderline cases, molecular tests that look at the genes of the lesion may be added.

The result is a written report that agrees, refines or disagrees with the first. That document goes to your treating team, who reconcile the two readings before finalizing anything.

Why do pathologists sometimes disagree about melanoma?

Melanocytic lesions, the family of growths made of pigment cells, sit on a spectrum. At one end is the ordinary mole almost everyone carries. At the other is a thick, ulcerated, clearly invasive melanoma. Between them lie atypical moles, unusual growths in children and young adults known as Spitz lesions, melanoma in situ, and thin invasive melanomas. The middle of that spectrum is where two honest, well-trained experts can look at the same cells and reach different conclusions.

The scale of that disagreement has been measured. In a study published in the BMJ and indexed on PubMed, 187 US pathologists interpreted a shared set of 240 skin biopsy slides that had been assigned a consensus reference diagnosis. For clearly benign moles, individual interpretations matched the reference about 92 percent of the time. For invasive melanoma at the thicker end, agreement was about 72 percent. In the middle categories, covering moderately and severely atypical lesions and melanoma in situ, agreement with the reference fell to roughly 25 to 43 percent.

Those numbers are not an indictment of pathologists. They describe a genuinely hard biological problem. Some lesions that receive a melanoma label may never have caused harm, a concern researchers describe as overdiagnosis. Under-calling carries the opposite risk: a lesion labeled benign that was in fact an early melanoma, treated with a narrow excision and no follow-up.

A second read lowers that uncertainty rather than eliminating it. Two specialists reaching the same conclusion is stronger evidence than one. Two reaching different conclusions is a signal your team needs, not a failure of the process. It tells them the case belongs in the gray zone, where cautious management and a frank conversation about uncertainty become part of the plan.

Melanoma pathology report explained: what the terms mean

A pathology report is written for other clinicians, so it reads like a dense telegram. Asking your team to walk through it line by line is reasonable. The table below covers the items that most often steer treatment, drawn from how the National Cancer Institute and the Mayo Clinic describe melanoma staging.

Report term	What it means in plain language	Why it matters
Breslow thickness	Depth in millimeters from the skin surface to the deepest melanoma cell	The single most influential factor in staging and in deciding surgical margins and lymph node testing
In situ vs invasive	In situ means cells stay in the top skin layer; invasive means they have entered the dermis	In situ melanoma has not yet gained access to blood or lymph vessels
Ulceration	The surface over the tumor is broken when viewed microscopically	Raises the stage within a given thickness
Mitotic rate	How many cells are actively dividing per square millimeter	A marker of how quickly the tumor is growing
Margins	Whether melanoma cells reach the edge of what was removed	Determines whether further surgery is needed
Lymphovascular invasion	Cells seen inside small vessels	Suggests a pathway for spread
Regression	Areas where the immune system appears to have attacked the tumor	Can make true thickness harder to measure

Two details deserve emphasis. First, thickness is measured to a tenth of a millimeter, and staging thresholds sit at specific cutoffs, so a second pathologist re-measuring the same slide can shift a case across a boundary. Second, a report that hedges with phrases such as favor, cannot exclude, or uncertain malignant potential is telling you the lesion is in the gray zone. That language is not sloppiness; it is an honest flag, and one of the strongest reasons to seek a second read.

Who usually benefits from a melanoma second opinion, and who may be asked to wait

Not every melanoma diagnosis needs a second microscope. Some do, urgently. The distinction is less about how frightened you feel and more about how much the plan depends on details that could reasonably change.

A second read tends to earn its place when the report uses uncertain language, when the lesion is described as Spitz-like, severely atypical or of uncertain malignant potential, or when the patient is a child or young adult, where benign mimics of melanoma are more common. It also matters when the tumor is thin and sits near a staging threshold, because a fraction of a millimeter can decide whether a sentinel lymph node biopsy is offered. Unusual sites such as the palms, soles, nail beds, mucous membranes or eye involve subtypes many general pathologists see rarely. And when the proposed plan includes lymph node surgery, imaging or drug therapy, the stakes of getting the foundation right rise with them.

People are sometimes advised that a second read is unlikely to change anything. That advice is usually reasonable when the diagnosis is unambiguous, has already been reviewed by a dermatopathologist or discussed at a tumor board, and the plan is a straightforward excision that would be the same under any plausible reading. It is also common when disease is already advanced and symptomatic, and the team judges that delaying treatment to re-examine slides carries more risk than benefit. Even then, a second read can proceed in parallel with care rather than ahead of it.

Being asked to wait is not the same as being refused. If you want a review, say so. Most clinicians will help arrange it, and the request itself does not commit you to changing anything.

Should I get a second opinion before melanoma surgery?

Timing is where second opinions either pay off or become a footnote. The first surgery for melanoma is usually a wide local excision, in which the surgeon removes the original site along with a rim of healthy-looking skin. The width of that rim is set by national guidelines according to Breslow thickness. Whether a sentinel lymph node biopsy is offered at the same operation also depends on thickness and ulceration. In other words, the surgical plan is essentially a translation of the pathology report.

That makes the window between diagnosis and surgery the most valuable time for a review. If a second pathologist measures the tumor as slightly thicker or thinner, or reclassifies in situ disease as invasive, the surgeon may adjust the margin or the decision about node testing before anything is done. After surgery, the slides still exist and a review remains possible, but the plan has already been executed; a revised reading may then require a second procedure or leave a question unanswered.

The natural worry is that pausing invites the tumor to grow. Melanoma is taken seriously precisely because it can spread, and no one should postpone care for months. Yet the interval needed to ship slides and obtain a second read is typically short in the context of a treatment pathway that already includes scheduling and staging. The NHS describes treatment as following diagnosis and staging rather than the biopsy itself, which is the same interval a review fits into.

Ask your surgeon directly: is a short pause for pathology review safe in my case? If they say yes, the review can usually be arranged while the operation stays booked. If they say no, they should explain why, and that reasoning belongs in your notes.

How does staging shape the treatment plan?

Staging is the process of describing how far a cancer has extended, and for melanoma it uses three pieces of information often abbreviated as TNM. T describes the tumor itself, chiefly Breslow thickness and ulceration. N asks whether nearby lymph nodes contain melanoma cells. M asks whether cells have traveled to distant organs. The National Cancer Institute’s patient summary lays out how these combine into stages from 0 (in situ) through IV.

For the many people diagnosed with thin, localized melanoma, staging is completed by the pathology report and a physical examination of the skin and lymph node areas. Guidelines from the NCI and others generally do not recommend blood tests or scans for early thin melanoma, because they rarely change management and can produce false alarms. A second-opinion plan review sometimes catches the opposite error: imaging ordered where it adds anxiety but not information.

Sentinel lymph node biopsy is the procedure in which a tracer injected near the tumor identifies the first node or nodes that drain the area, which are then removed and examined. It is usually discussed for melanomas above a guideline-defined thickness or with ulceration. Whether it is offered, and whether the result would alter what happens next, is a legitimate question for a second team. Some people want the prognostic information; others, after hearing the risks and what the result would and would not change, decline it. Both are defensible choices made with a clinician.

For melanoma that has reached the nodes or beyond, a tissue test for a BRAF mutation, a change in a gene that drives some melanomas to grow, becomes part of standard staging because it determines which classes of drug therapy are even relevant. A plan review would confirm that test has been requested.

Which treatments might a second opinion revisit?

Surgery remains the cornerstone for localized melanoma, and for most thin tumors it is the whole treatment, followed by skin checks. A second opinion at that stage rarely changes the type of treatment; it checks the margin, the node decision and the follow-up schedule.

The picture broadens when disease has reached the lymph nodes or beyond, or when the primary tumor is thick. Here the plan may include adjuvant therapy, meaning treatment given after surgery to reduce the chance of the cancer returning. Two drug classes dominate current guidelines, as summarized by the National Cancer Institute. Immune checkpoint inhibitors are antibodies that block proteins, such as PD-1 or CTLA-4, that normally act as brakes on immune cells; releasing those brakes allows the immune system to attack melanoma. Targeted therapy pairs a BRAF inhibitor with a MEK inhibitor to shut down the growth signal in tumors carrying a BRAF mutation, which is why the gene test matters. Both classes are given over months according to protocols set by the oncologist, and both carry distinct side effect profiles that a second team can help you weigh.

People frequently ask what the newest breakthrough is. The honest answer is that checkpoint immunotherapy and BRAF-targeted therapy transformed advanced melanoma care over roughly the past decade and remain the backbone. Active research now focuses on giving these drugs before surgery, on combining them, and on treating earlier stages. Whether any of that applies to you is a question for your oncologist, not a headline.

A plan review also asks about clinical trials, radiation for specific situations, and whether observation with scheduled follow-up is a reasonable alternative. Any change to a prescribed regimen belongs to the prescribing clinician.

What is the 2 week rule for melanoma?

Readers in the United Kingdom will recognize the phrase; readers elsewhere often encounter it in forums and wonder whether they have missed a deadline. The 2 week rule is a feature of the NHS referral system. When a general practitioner sees a mole or skin change that raises suspicion of melanoma, they make an urgent referral, and the NHS states that the person should see a specialist within 2 weeks. It is a promise about access to assessment, not a countdown to surgery or a statement about how fast melanoma grows.

The United States has no equivalent statutory target. Guidance from bodies such as the American Academy of Dermatology and the NCI emphasizes prompt evaluation of suspicious lesions, and most dermatology practices will prioritize a changing or bleeding mole, but the timing depends on local access rather than a national rule.

Why does this matter for a second opinion? Because people sometimes read the 2 week figure as evidence that every step must be compressed into a fortnight, and conclude they cannot afford a pathology review. In practice the rule governs the first specialist visit. Diagnosis, staging and planning follow it, and a slide review sits comfortably inside that phase. The NHS itself describes the pathway as referral, biopsy, then results and a treatment plan.

The more useful lesson from the rule is the one it encodes: a changing pigmented spot deserves professional eyes soon rather than someday. That urgency applies before diagnosis. After diagnosis, the goal shifts from speed alone to getting the foundation right, and a few extra days for an expert second read is usually consistent with that goal. Your treating team is the right judge of whether your case is the exception.

What do the following days and weeks usually look like?

Once you decide on a review, the sequence is fairly predictable, even if the waiting is not.

The first days are paperwork. You or your clinic contact the laboratory that processed the biopsy, sign a release, and ask for the slides and report to be sent to the reviewing pathologist, or for a digital scan if that lab offers one. Some labs send a set of recut slides and keep the originals; others ship the originals and expect them back. Ask which, so nothing is lost in transit.

While the slides travel, the plan review can move in parallel. A melanoma team can read your existing report, examine you, and outline what they would recommend under each plausible pathology outcome. That parallel approach is the main way people avoid the review adding time to the pathway.

The middle stretch is the read itself. If the case is straightforward, the second report may follow quickly. If the pathologist orders deeper sections or special stains, the wait lengthens, and that is usually a sign of diligence rather than a problem. Laboratories can tell you their expected turnaround; asking is fair.

The final step is reconciliation. Your treating team receives the second report and compares it with the first. Agreement confirms the plan. A small difference in thickness may adjust margins or the node discussion. A larger disagreement typically prompts a conversation between the two pathologists, sometimes a third read, and a frank talk with you about managing uncertainty.

Through all of it, ordinary life continues. Keep the biopsy site clean and covered as instructed, use sun protection, continue any medicines you already take, and write questions down as they occur to you. The list you bring to the reconciliation visit is worth more than any single answer you find online.

What people often get wrong

Some misunderstandings about melanoma second opinions surface again and again, and each can steer a decision the wrong way.

The first is that asking for one signals distrust. Clinicians request second reads on their own patients’ slides constantly; it is routine quality practice, and most dermatologists and oncologists will help you arrange one. The relationship survives.

The second is that a second opinion requires another biopsy. In almost all cases the existing slides and wax block hold everything a reviewer needs. Additional sampling is the exception, requested only when the first specimen did not capture enough tissue.

The third is that a diagnosis of melanoma is a binary test result, like a blood sugar reading. As the BMJ study on PubMed showed, interpretation is reproducible at the extremes and far less so in the middle. Knowing your lesion sits in that middle changes how you should weigh advice.

The fourth is that a second opinion which simply agrees was wasted effort. Concordance is the most common outcome, and it is valuable: it converts one expert’s judgment into two, which is precisely the reassurance many people are seeking when they consider a review in the first place.

The fifth is that in situ melanoma is not really cancer and needs no follow-up. It is an early form, confined to the top layer of skin, and treatment is usually surgical, but people who have had it carry a higher lifetime risk of another melanoma than the general population, according to the NCI. Lifelong skin examinations remain part of the plan.

The sixth is that reviews must come from far away to count. Expertise in melanoma pathology exists in many regions. What matters is the reviewer’s specialization, not the distance the slides travel.

How to get melanoma slides reviewed without delaying treatment or offending your doctor

The practical steps are less daunting than they sound, and framing them well keeps everyone on the same side.

Start with the conversation. Tell your dermatologist or surgeon that you would like a pathology second opinion and, if you want one, a plan review as well. A simple sentence works: I would feel more settled going into surgery if another dermatopathologist confirmed the reading. Most clinicians respond by offering to send the slides themselves, often to a colleague they already use for difficult cases. Accepting that offer is fine; you can also name a center of your choosing.

Next, get your documents. Ask for a copy of the full pathology report, not just the summary line, plus the clinical notes describing the lesion and any photographs. In the United States, federal privacy law gives you the right to obtain your medical records, including pathology materials, though laboratories may charge a handling fee and set their own procedures for releasing slides. Ask the lab whether they send originals, recuts or digital scans, and how they track the return.

Then coordinate the calendar. Keep any scheduled appointments and, if surgery is booked, ask whether it should stay on the books pending the review. Many teams prefer to hold the date and adjust only if the second report changes the plan. Do not cancel steps unilaterally, and do not stop or start any medication on the strength of a review you are still waiting for.

Finally, make sure both teams talk to each other. Give the reviewing team your treating clinician’s contact details, and vice versa. A second opinion that lands in your inbox but never reaches the surgeon has not done its job. The decision about what to do with it belongs to the team treating you.

Questions to ask your care team

Good questions do two things: they surface the uncertainty in your specific case, and they leave a record of what was said. Bring these to whichever clinician is coordinating your care, and add your own.

• Was my biopsy read by a dermatopathologist, or by a general pathologist? Has anyone else already reviewed the slides?
• Which parts of my report are certain, and which involve judgment? Is my lesion near any staging threshold?
• If a second pathologist measured the thickness slightly differently, would my surgical margin or the lymph node discussion change?
• Is a short pause for pathology review safe in my case? If not, what specifically makes waiting risky?
• Can the plan review happen in parallel with the slide review so no time is lost?
• Was a BRAF test, or any other molecular test, performed or planned, and would the result change anything?
• Is sentinel lymph node biopsy being offered, not offered, or left to my preference, and what would each result mean for what happens next?
• Are scans or blood tests recommended for my stage, and what do guidelines say about their value here?
• If adjuvant therapy is being discussed, what is the mechanism, what are the main side effects, and what is the alternative of observation?
• Are there clinical trials I would be eligible for, and how would I find out?
• What follow-up schedule will I have, who performs the skin checks, and for how long?
• If the two pathology opinions disagree, how will you resolve it, and will I be part of that conversation?

Write the answers down or ask permission to record them. Diagnoses land hard, and memory is unreliable in the days that follow. A written record also lets you compare what two teams said without relying on impression.

When to call your doctor

A second opinion is about slides and plans, but your body keeps moving while the paperwork travels. Certain changes should not wait for the next scheduled visit, regardless of where you are in the review.

Call your treating team promptly if the biopsy site shows spreading redness, warmth, pus, increasing pain or a fever, which can signal infection. Call if you notice a new lump or firm nodule near the scar, or a swelling in the armpit, groin or neck on the same side, since these are the lymph node regions that drain the skin. Any pigmented spot anywhere on your body that is changing in size, shape or color, itching persistently or bleeding also deserves a same-week appointment, both because it may be a separate lesion and because people with one melanoma carry an elevated risk of another.

Seek urgent care for symptoms that could indicate spread or a complication: new persistent headache, vision changes, confusion or seizure; shortness of breath or chest pain; unexplained weight loss or bone pain that does not settle; yellowing of the skin or eyes. These are uncommon in early melanoma, but they warrant prompt assessment rather than reassurance from a forum.

Call as well if you are on immunotherapy or targeted therapy and develop severe diarrhea, a widespread rash, extreme fatigue, or any new symptom your oncologist has told you to report, because these drug classes can affect organs in ways that need early attention.

And call if the second opinion contradicts the first and no one has explained what happens next. Silence after conflicting reports is not a plan. Your treating team owns the decision, and they should know as soon as you do that new information exists.

Frequently asked questions

What is the 2 week rule for melanoma?

It is an NHS standard in the United Kingdom under which a general practitioner’s urgent referral for suspected melanoma should lead to a specialist appointment within 2 weeks. It concerns access to assessment, not a deadline for surgery. The United States has no equivalent rule, though guidelines stress prompt evaluation of any changing or bleeding mole. A pathology second opinion fits within the staging phase that follows the first specialist visit.

How likely is it to get a second melanoma?

People who have had one melanoma have a higher risk of developing a new, separate melanoma than the general population, according to the National Cancer Institute. The exact risk depends on skin type, sun exposure history, number of atypical moles and family history, so no single figure applies to everyone. This is why lifelong skin examinations, both professional and self-directed, remain part of follow-up even after early-stage disease.

What is the newest breakthrough in melanoma treatment?

Immune checkpoint inhibitors, which release brakes on the immune system, and targeted therapy for BRAF-mutated tumors are the classes that changed advanced melanoma care over roughly the past decade and remain the standard described by the National Cancer Institute. Current research is testing these drugs before surgery, in combination, and at earlier stages. Whether any of this applies to your case is a question only your oncologist can answer.

Am I considered a cancer survivor if I had melanoma?

Yes. The National Cancer Institute defines a cancer survivor as anyone from the moment of diagnosis through the rest of life, regardless of stage or treatment. That includes people treated for melanoma in situ. Some people find the term empowering; others prefer not to use it. Either choice is valid, and it does not change the medical recommendation for ongoing skin checks.

How often is melanoma misdiagnosed?

Misdiagnosis rates depend heavily on the type of lesion. In a BMJ study indexed on PubMed, pathologists agreed with a reference diagnosis about 92 percent of the time for clearly benign moles and about 72 percent for thicker invasive melanomas, but only roughly 25 to 43 percent for atypical moles and melanoma in situ. Ambiguous lesions in that middle zone are where a second read is most likely to add information.

Do I need a new biopsy for a second opinion?

Usually not. The tissue from your original biopsy is preserved in a wax block and on glass slides, and a second pathologist can review those directly or through a digital scan. If the reviewer needs more, they can request deeper sections cut from the same block or special stains. A repeat biopsy is only considered when the original sample did not capture enough of the lesion to answer the question.

Can a second opinion downgrade a melanoma diagnosis?

It can, and it can also upgrade one. A second pathologist might measure the tumor as thinner, reclassify a lesion as an atypical mole, or conversely identify invasion the first read did not describe. Both directions matter because they change surgical margins and the lymph node discussion. When two opinions conflict, teams typically arrange a direct discussion between pathologists or a third read before finalizing the plan.

What is a dermatopathologist and why does it matter?

A dermatopathologist is a physician trained in both pathology and dermatology who specializes in examining skin tissue under the microscope. Because melanocytic lesions range along a spectrum from benign mole to invasive melanoma, specialists who see hundreds of these cases are better positioned to interpret the gray-zone ones. Asking whether your slides were read by a dermatopathologist is a reasonable first question before deciding on a second opinion.

How long does a melanoma pathology review take?

There is no single standard. Time depends on how quickly the original laboratory releases slides, whether they are shipped or scanned, and whether the reviewing pathologist orders deeper sections or special stains, which lengthen the process. Laboratories can tell you their expected turnaround, and asking is appropriate. Many teams run the plan review in parallel so the slide review does not add time to the overall pathway.

Is melanoma in situ really cancer?

Melanoma in situ is the earliest form, in which abnormal melanocytes are confined to the top layer of skin and have not reached the dermis where blood and lymph vessels lie. It is treated, usually by surgical removal with a margin, because left alone it can progress. People with a history of in situ melanoma carry an increased risk of future melanomas, so ongoing skin checks are recommended by the NCI and other bodies.

References

• Melanoma skin cancer, NHS
• Melanoma, Cleveland Clinic
• Melanoma, MedlinePlus

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.